Previous 10 | Next 10 |
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the China National Medical Products Administra...
Are These The Best Biotech Stocks To Buy Right Now? In the stock market, many investors bank on the prospect of a company rather than what it currently has to offer. Biotech stocks would be a prime example for this investment approach. The industry includes companies that develo...
Chinese President Xi Jinping directed that the government is committed to "deliver its economic growth target and support the healthy growth of internet platform companies." The edict from Xi himself is highly significant. He is committed to leveraging Alibaba and its peers to help me...
Gainers: Finch Therapeutics (FNCH) +46%. Zymeworks (ZYME) +44%. Lantheus (LNTH) +13%. BeiGene (BGNE) +12%. Inari Medical (NARI) +11%. Losers: Accolade (ACCD) -55%. Aldeyra Therapeutics (ALDX) -15%. Venus Concept (VERO) -14%. Bio...
Beijing-based BeiGene (NASDAQ:BGNE) announced the groundbreaking of its flagship U.S. manufacturing and clinical R&D center at the Princeton West Innovation Campus in Hopewell, New Jersey. The company said initial phase of construction is expected to include ~400K square feet of comm...
Flagship U.S. Facility Will Include Biologic Manufacturing and Late Stage Research and Clinical Development of Innovative Cancer Medicines Sixth U.S. Location Adds to Global Expansion and Brings New Jobs to New Jersey BeiGene, Ltd . (NASDAQ: BGNE; HKEX: 06160; SS...
BBH’s price multiples indicate an undervaluation and its major holdings have started recording significant price growth. BBH has strong fundamentals and has performed well enough in the medium and long term. BBH will face some minor ups and downs since most stocks are yet t...
BeiGene (NASDAQ:BGNE) said its medicine Brukinsa was approved in Uruguay to treat adult patients with previously treated mantle cell lymphoma (MCL), relapsed or refractory marginal zone lymphoma (MZL), and Waldenström's macroglobulinemia (WM). BeiGene added that Adium will ...
BRUKINSA is now available in four countries in Latin America, following previous approvals in Brazil, Chile, and Ecuador Under an exclusive distribution agreement, Adium will commercialize BRUKINSA in Latin America BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688...
Plenary presentation of Phase 3 tislelizumab trial in first-line RM-NPC Primary analysis of zanubrutinib Phase 2 ROSEWOOD trial in follicular lymphoma Long-term data from zanubrutinib Phase 3 trial in Waldenström macroglobulinemia BeiGene (NASDAQ: BGNE; ...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...